Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06360419 · ClinicalTrials.gov registry record · Phase 3
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
A Phase 3 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 346
- Enrollment target
NCT06360419 is a Phase 3 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 346 participants.
The verdict
NCT06360419, a Phase 3 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 346 participants
- Enrollment target
Study Summary
PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.
Interventions
- DRUG Placebo
- DRUG Solriamfetol 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2025-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06360419
The ClinicalTrials.gov registry entry for NCT06360419 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06360419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06360419 about?
NCT06360419 is a clinical study titled "Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol". PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.
What is the current status of trial NCT06360419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 346 participants. The study started on 2024-03-18. Estimated completion is 2025-03-26.
What interventions are being tested in trial NCT06360419?
The interventions under investigation include: Placebo (DRUG), Solriamfetol 300 mg (DRUG).
Who is sponsoring clinical trial NCT06360419?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.